Abstract
Background and Objectives
Carvedilol is a drug of choice in treatment of portal hypertension. The present study was designed to elucidate the potential role of antifibrotic effects of carvedilol in improving hepatic efficiency and the carvedilol oral pharmacokinetic changes during induction of liver fibrosis.
Methods
Rats were given CCl4 (1 ml/kg, intraperitoneal) twice weekly for 6 weeks and/or co-treated with carvedilol (10 mg/kg, orally) three times weekly on alternating days. Indocyanine green (ICG) clearance test was used as a modality for the measurement of hepatic blood flow. In addition, assessment of serum albumin as a marker of synthetic capacity and immunohistochemical staining of P-glycoprotein (P-gp) expression as a marker of metabolic capacity were done. Furthermore, hydroxyproline and TGF-β1 were detected as markers of liver fibrosis.
Results
The area under plasma concentration–time curve of a single dose of carvedilol was significantly increased, associated with decreased the clearance in rats intoxicated with CCl4 compared to control group. Carvedilol co-treatment in CCl4-intoxicated rats for 6 weeks significantly counteracted the changes in hepatotoxicity markers and histopathological lesions induced by CCl4. In addition, there were no significant alterations in carvedilol pharmacokinetics between control and CCl4-intoxicated rats. Furthermore, carvedilol treatment restored liver efficiency, including synthetic and metabolic capacity as well as hepatic blood flow.
Conclusion
The present study provides evidence underlying the antifibrotic effects of carvedilol and enhancement of hepatic efficiency. In addition, the pharmacokinetic parameters of a single dose of carvedilol are altered in liver fibrosis, manifested as delayed clearance. This was attributed to the reduction of both hepatic blood flow and CYP2D6 expression in the liver. Carvedilol co-treatment in CCl4-intoxicated rats for 6 weeks recovered its pharmacokinetic profile, which is mainly attributed to the impact of pharmacodynamic antifibrotic effects of carvedilol on its own kinetics.
Similar content being viewed by others
References
Pinzani M, Rosselli M, Zuckermann M. Liver cirrhosis. Best Pract Res Clin Gastroenterol. 2011;25:281–90.
Moal F, Veal N, Vuillemin E, Barriere E, Wang J, Fizanne L, et al. Hemodynamic and antifibrotic effects of a selective liver nitric oxide donor V-PYRRO/NO in bile duct ligated rats. World J Gastroenterol. 2006;12:6639–45.
Rockey DC. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology. 2000;118:1261–5.
Laleman W, Nevens F. Cirrhotic portal hypertension: current and future medical therapy for primary and secondary prevention of variceal bleeding. Minerva Med. 2006;97:325–45.
Tripathi D, Hayes PC. The role of carvedilol in the management of portal hypertension. Eur J Gastroenterol Hepatol. 2010;22:905–11.
Li T, Ke W, Sun P, Chen X, Belgaumkar A, Huang Y, Xian W, Li J, Zheng Q. Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. BMJ Open. 2016;6(5):e010902.
Hamdy N, El-Demerdash E. New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage. Toxicol Appl Pharmacol. 2012;261:292–9.
Liu J, Takase I, Hakucho A, Okamura N, Fujimiya T. Carvedilol attenuates the progression of alcohol fatty liver disease in rats. Alcohol Clin Exp Res. 2012;36:1587–99.
Araujo Junior RF, Garcia VB, Leitao RF, Brito GA, Miguel Ede C, Guedes PM, Araujo AA. Carvedilol improves inflammatory response, oxidative stress and fibrosis, in the alcohol-induced liver injury in rats by regulating kuppfer cells and hepatic stellate cells. PLoS One. 2016;11(2):e0148868.
Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 1994;26:335–46.
Schaefer WH, Politowski J, Hwang B, Dixon F Jr, Goalwin A, Gutzait L, et al. Metabolism of carvedilol in dogs, rats, and mice. Drug Metab Dispos. 1998;26:958–69.
Brodde OE, Kroemer HK. Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53:814–22.
Neugebauer G, Gabor M, Reiff K. Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction. J Cardiovasc Pharmacol. 1992;19(Suppl 1):S142–6.
Klotz U. Antiarrhythmics: elimination and dosage considerations in hepatic impairment. Clin Pharmacokinet. 2007;46:985–96.
Starkel P, Leclercq IA. Animal models for the study of hepatic fibrosis. Best Pract Res Clin Gastroenterol. 2011;25:319–33.
Yaoita H, Sakabe A, Maehara K, Maruyama Y. Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. Circulation. 2002;105:975–80.
Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 1957;28:56–63.
Bayraktar N, Devay SD, Taslipinar MY, Omeroglu S, Gumuslu S, Kavutcum M, Canbolat O. The effects of stobadine on purine metabolism in rats treated with carbon tetrachloride. Turk J Med Sci. 2012;42:894–900.
Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys. 1961;93:440–7.
Abdel Fattah LE, Mohamed TA, Taha EA. Spectrofluorimetric determination of carvedilol in dosage form and spiked human plasma through derivatization with 1-dimethylaminonaphthalene-5-sulphonyl chloride. CI CEQ 2010;16:31–8.
Hakucho A, Liu J, Liu X, Fujimiya T. Carvedilol improves ethanol-induced liver injury via modifying the interaction between oxidative stress and sympathetic hyperactivity in rats. Hepatol Res. 2014;44:560–70.
Breikaa RM, Algandaby MM, El-Demerdash E, Abdel-Naim AB. Multimechanistic antifibrotic effect of biochanin a in rats: implications of proinflammatory and profibrogenic mediators. PLoS One. 2013;8:e69276.
Liu Y, Wang Z, Kwong SQ, Lui EL, Friedman SL, Li FR, et al. Inhibition of PDGF, TGF-beta, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol. 2011;55:612–25.
Nelson DL, Cox MM. The three-dimensional structure of proteins. In: Lehninger AL, editor. Lehninger: principles of biochemistry. 4th ed. New York: Freeman WH; 2004.
Mahmud Z, Bachar S, Qais N. Antioxidant and hepatoprotective activities of ethanolic extracts of leaves of premna esculenta Roxb. against carbon tetrachloride-induced liver damage in rats. J Young Pharm. 2012;4:228–34.
Peterson TC, Hodgson P, Fernandez-Salguero P, Neumeister M, Gonzalez FJ. Hepatic fibrosis and cytochrome P450: experimental models of fibrosis compared to AHR knockout mice. Hepatol Res. 2000;17:112–25.
Ibrahim ZS, Ishizuka M, Soliman M, ElBohi K, Sobhy W, Muzandu K, et al. Protection by Nigella sativa against carbon tetrachloride-induced downregulation of hepatic cytochrome P450 isozymes in rats. Jpn J Vet Res. 2008;56:119–28.
Chin KV, Chauhan SS, Pastan I, Gottesman MM. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ. 1990;1:361–5.
Wang P, Chaudry IH. Mechanism of hepatocellular dysfunction during hyperdynamic sepsis. Am J Physiol. 1996;270:R927–38.
Yang YL, Di L, Duan YY, Liu X, Liu J, Yang RJ, et al. A prospective experimental study of liver fibrosis with ultrasound and its correlation with hepatic reserve function and hemodynamics. BMC Gastroenterol. 2012;12:168.
Banares R, Moitinho E, Piqueras B, Casado M, Garcia-Pagan JC, de Diego A, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology. 1999;30:79–83.
Lin HC, Yang YY, Hou MC, Huang YT, Lee FY, Lee SD. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. Am J Gastroenterol. 2004;99:1953–8.
Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64:1147–61.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No funding has been received for the conduct of this study.
Conflict of interest
All authors declare that they have no competing financial or personal interest or any kind of conflict of interest relevant to this study.
Ethical approval
All animal procedures were carried out in strict accordance with the internationally accepted principles for laboratory animal use and care. The study was approved by the Research Ethical Committee of the Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Rights and permissions
About this article
Cite this article
El-Demerdash, E., Abdel-Sattar, S.A., El-Bakly, W.M. et al. Antifibrotic Effects of Carvedilol and Impact of Liver Fibrosis on Carvedilol Pharmacokinetics in a Rat model. Eur J Drug Metab Pharmacokinet 42, 767–779 (2017). https://doi.org/10.1007/s13318-016-0391-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-016-0391-9